Second revised consensus on melanoma of the skin;Tweede herziene consensus melanoom van de huid

Nederlands Tijdschrift voor Geneeskunde

Volumn 141, Issue 42, 1997, Pages 2015-2019

  Kroon, B B R ^a,b   Bergman, W ^a,c   Coebergh, J W W ^a,d   Ruiter, D J ^a   Van Everdingen, J J E ^e  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Centraal Begeleidingsorgaan V I   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

DYSPLASTIC NEVUS; EXCISION; FOLLOW UP; HUMAN; MELANOMA; NETHERLANDS; PRACTICE GUIDELINE; RISK FACTOR; SHORT SURVEY; SURVIVAL;

BIOPSY; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; MELANOMA; PHYSICAL EXAMINATION; PRECANCEROUS CONDITIONS; RADIOTHERAPY; RISK FACTORS; SKIN NEOPLASMS;

EID: 0030828327     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (25)

1. Rampen FHJ, Rümke Ph. Consensus melanoom van de huid. Ned Tijdschr Geneeskd 1985;129:785-8.
2. Rampen FHJ, Ruiter DJ, Kroon BBR, Rümke Ph Herziene consensus melanoom van de huid. Ned Tijdschr Geneeskd 1990;134: 2031-3.
3. Netherlands Cancer Registry. Incidence of cancer in the Netherlands, 1993. Utrecht: Vereniging Integrale Kankercentra, 1996.
4. Coebergh JWW, Heijden LH van der, Janssen-Heijnen MLG, editors. Cancer incidence and survival in the South-east of the Netherlands, 1955-1994. A report from the Eindhoven Cancer Registry. Eindhoven: Comprehensive Cancer Center South. 1995:48-53.
5. Tersmette AC, Coebergh JWW, Casparie-van Velsen IJA, Ruiter DJ, Rhee HJ van der, Welvaart K. Invasive cutaneous melanoma in the Netherlands, 1989-1990. Eur J Cancer Prev 1996;5:69-74.
6. MacKie RM, Freudenberger T, Aitchison TC. Personal risk factors chart for cutaneous melanoma. Lancet 1989;ii:487-90.
7. Whiteman D, Green A. Melanoma and sunburn. Cancer Causes Control 1994;5:564-72.
8. Veronesi U, Cascinelli N. Narrow excision (1 cm margin). A safe procedure for thin cutaneous melanoma. Results of an international randomized trial. Arch Surg 1991;126:438-41.
9. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas ( 1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262-9.
10. Elder DE, Murphy GF. Melanocytic tumors of the skin. Atlas of tumor pathology. 3rd series. Fascicle 2. Washington: Armed Forces Institute of Pathology, 1991.
11. Mooi WJ, Krausz T, Biopsy pathology of melanocytic disorders. Biopsy pathology series 17. London: Chapman & Hall, 1992.
12. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49: 2420-30.
13. Balch CM, Soong S-J, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
14. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
15. Meijer S, Pijpers HJ, Veen H van der, Paul MA, Hattum AH van. Hockstra OS. Schildwachtklieronderzoek om melanoompatiënten te selecteren voor regionale lymfklierdissectie. Ned Tijdschr Geneeskd 1994;138:2491-5.
16. Kapteijn BAE, Nieweg OE, Liem IH, Mooi WJ, Balm AJM, Muller SH, et al. Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 1997;4: 156-60.
17. Jonk A, Kroon BBR, Rümke P, Mooi WJ, Hart AAM, Dongen JA van. Lymph node metastasis from melanoma with an unknown primary site. Br J Surg 1990;77:665-8.
18. Liénard D, Eggermont AMM, Schraffordt Koops H, Kroon BBR, Rosenkaimer F, Autier P. et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994;4 Suppl 1:21-6.
19. Schraffordt Koops H, Vaglim M, Kroon BBR, Thompson JF, Gohl J, Eggermont AMM, et al. Value of prophylactic isolated limb perfusion (ILP) for stage I high risk malignant melanoma. A randomized phase III trial. 4th World conference on melanoma, Sydney 1997. Melanoma Res 1997;7 Suppl 1:834.
20. Overgaard J, Gonzalez Gonzalez D, Hulshof MCCM, Arcangeli G, Dahl O. Mella O. et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995; 345:540-3.
21. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC. Blum RH Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
22. Bergman W, Voorst Vader PC van, Ruiter DJ. Dysplastische naevi en het risico op melanoom een richtlijn voor patiëntenzorg. Ned Tijdschr Geneeskd 1997;141:2010-4.
23. Raeve LE de, Coninck AL de, Dierickx PR, Roseeuw DI. Neonatal curettage of giant congenital melanocytic nevi Arch Dermatol 1996; 132:20-2.
24. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 1995;221:566-71.
25. MacKie RM, Bufalino R, Morabito A, Sutherland C, Cascinelli N. Lack of effect of pregnancy on outcome of melanoma. For the World Health Organisation Melanoma Programme. Lancet 1991; 337:653-5.